Melanoma, Cancer Immunotherapy and Development Therapeutics Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale, Napoli, Italy.
Kidney Cancer Program, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z.
Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.
免疫疗法代表了癌症系统治疗史上继化疗和靶向治疗之后的第三次重要浪潮，目前已成为多种癌症的一种有效治疗选择。抗细胞毒性 T 淋巴细胞相关抗原（CTLA）-4 抗体和程序性死亡（PD）-1/PD-配体（L）1 抗体在黑色素瘤和其他癌症中的临床成功，促使人们越来越关注其他免疫疗法的发展（例如，具有其他免疫靶点的单克隆抗体、过继细胞转移和疫苗），目前全球有超过 3000 项免疫肿瘤学试验正在进行，涉及全球数百个研究所。这些不同的免疫治疗选择相互结合以及与其他治疗方式结合的潜在用途是一个特别有希望的领域。第三届免疫治疗桥接会议（2017 年 11 月 29-30 日，意大利那不勒斯）重点关注了各种癌症类型的免疫治疗最新进展，本报告对此进行了总结。
